Farallon Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Farallon Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,000	Closed	-$676K	–	100
2026 Q1	$676K	Hold	4,000	–	–	﹤0.01%	105
2025 Q4	$731K	Hold	4,000	–	–	﹤0.01%	91
2025 Q3	$486K	Hold	4,000	–	–	﹤0.01%	93
2025 Q2	$418K	Hold	4,000	–	–	﹤0.01%	94
2025 Q1	$467K	Hold	4,000	–	–	﹤0.01%	96
2024 Q4	$338K	Hold	4,000	–	–	﹤0.01%	108
2024 Q3	$359K	Hold	4,000	–	–	﹤0.01%	115
2024 Q2	$322K	Hold	4,000	–	–	﹤0.01%	115
2024 Q1	$319K	Hold	4,000	–	–	﹤0.01%	131
2023 Q4	$318K	Sell	4,000 -121,653	-97%	-$8.13M	﹤0.01%	118
2023 Q3	$8.78M	Sell	125,653 -147,147	-54%	-$11M	0.04%	90
2023 Q2	$19.6M	Buy	+272,800	New	+$20.1M	0.1%	79
2020 Q1	–	Sell	-442,222	Closed	-$45.7M	–	105
2019 Q4	$45.7M	Buy	442,222 +42,222	+11%	+$1.71M	0.31%	58
2019 Q3	$8.1M	Buy	+400,000	New	+$10.3M	0.06%	87

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Farallon Capital Management's AXSM Position: Q2 2026 in Review

Farallon Capital Management sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 4,000 shares — an estimated $676K sold.

Farallon Capital Management first reported a position in AXSM in Q3 2019 and held it in 14 quarters. The position peaked at $45.7M in Q4 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Farallon Capital Management reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Farallon Capital Management sold 4,000 Axsome Therapeutics shares in Q2 2026, an estimated $676K.
Farallon Capital Management first reported a position in Axsome Therapeutics in Q3 2019 and held it in 14 quarters.
Farallon Capital Management's Axsome Therapeutics position peaked at $45.7M in Q4 2019.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.